[1]蒋娅,李波.心肌瘢痕研究进展[J].心血管病学进展,2016,(1):66-69.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.017]
 JIANG Ya,LI Bo.Research Progress of Myocardial Scar[J].Advances in Cardiovascular Diseases,2016,(1):66-69.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.017]
点击复制

心肌瘢痕研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年1期
页码:
66-69
栏目:
综述
出版日期:
2016-02-20

文章信息/Info

Title:
Research Progress of Myocardial Scar
作者:
蒋娅李波
昆明医科大学第二附属医院心功能科,云南 昆明 650101
Author(s):
JIANG YaLI Bo
Department of Cardiac Function,The Second Affiliated Hospital of Chongqing Medical University,Kunming 650101,Yunnan,China
关键词:
心肌瘢痕 心脏再生 心律失常 心脏再同步化治疗
Keywords:
Myocardial scar Cardiac regeneration Cardiac arrhythmia Cardiac resynchronization therapy
分类号:
R542.2
DOI:
10.16806/j.cnki.issn.1004-3934.2016.01.017
文献标志码:
A
摘要:
瘢痕修复是心肌梗死后最常见的修复方式,心外膜来源细胞与骨髓来源细胞相互作用提供了瘢痕形成的细胞骨架,磷脂酶D1可抑制梗死后心室重塑,减少瘢痕形成,白介素-1拮抗剂是瘢痕缺陷愈合的治疗靶点。心脏干细胞释放的细胞因子在再生疗法中的作用,碎裂QRS波预测非透壁心肌瘢痕价值有限,交界区心肌瘢痕与室性心律失常密切相关。心肌瘢痕会引起心脏再同步化治疗无应答。
Abstract:
Scar formation is the most common method of repairing after myocardial infarction.The interaction between epicardium derived cell and bone marrow derived blood cell provide the cytoskeleton of scar formation. Additionally the combination of epicardium derived cell and bone marrow derived blood cell provide the cytoskeleton of scar formation, and phospholipase D1 can inhibit left ventricular remodeling after infarction, reducing scar formation.The interleukin 1 antagonist is the therapeutic targets to prevent defective scar healing. The role of stem cells related to paracrine factor should be emphasized in the treatment of alternative therapy in myocardial regeneration therapy. The value of fragmented QRS wave in the prediction of non transmural cardiac scar is limited and border-zone infarcts are closely related to ventricular arrhythmia.Myocardial scar is also related to the non-response of cardiac resynchronization therapy.

参考文献/References:

[1] Ruiz-Villalba A,Simon AM,Pogontke C,et al.Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar[J]. J Am Coll Cardiol,2015,65(19):2057-2066.
[2] Grothusen C, Hagemann A, Attmann T, et al. Impact of an interleukin-1 receptor antagonist and erythropoietin on experimental myocardial ischemia/reperfusion injury[J]. Sci World J,2012,2012:737585.
[3] Baumer Y, Leder C, Ziegler M, et al.The recombinant bifunctional protein alphacd133-GPVI promotes repair of the infarcted myocardium in mice[J]. J Thromb Haemost,2012,10(6):1152-1164.
[4] Ziegler M, Elvers M, Baumer Y, et al.The bispecific SDF1-GPVI fusion protein preserves myocardial function after transient ischemia in mice[J]. Circulation, 2012,125(5):685-696.
[5] Schonberger T, Jurgens T, Muller J, et al. Pivotal role of phospholipase D1 in tumor necrosis factor-alpha-mediated inflammation and scar formation after myocardial ischemia and reperfusion in mice[J]. Am J Pathol,2014,184(9):2450-2464.
[6] Abbate A,van Tassell BW, Biondi-Zoccai GG. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events[J]. BioDrugs,2012,26(4):217-233.
[7] Toldo S, Schatz AM, Mezzaroma E, et al.Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse[J]. Cardiovasc Drugs Ther,2012,26(3):273-276.
[8] Laflamme MA, Murry CE. Heart regeneration[J]. Nature,2011,473(7347):326-335.
[9] Doppler SA, Deutsch MA, Lange R, et al. Cardiac regeneration: current therapies—future concepts[J]. J Thorac Dis,2013,5(5):683-697.
[10] Hastings CL, Roche ET, Ruiz-Hernandez E, et al. Drug and cell delivery for cardiac regeneration[J]. Adv Drug Deliv Rev,2015,84:85-106.
[11] Li N, Wang C, Jia L,et al. Heart regeneration, stem cells, and cytokines[J]. Regen Med Res,2014,2(1):6.
[12] Steinhauser ML,Lee RT.Regeneration of the heart[J].EMBO Mol Med,2011,3(12):701-712.
[13] Couzin-Frankel J. The elusive heart fix[J]. Science,2014,345(6194):252-257.
[14] Mingliang R,Bo Z,Zhengguo W. Stem cells for cardiac repair:status, mechanisms, and new strategies[J]. Stem Cells Int,2011,2011:310928.
[15] Duran JM, Makarewich CA, Sharp TE, et al. Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms[J]. Circ Res,2013,113(5):539-552.
[16] Latham N, Ye B, Jackson R, et al.Human blood and cardiac stem cells synergize to enhance cardiac repair when cotransplanted into ischemic myocardium[J]. Circulation,2013,128(11 Suppl 1):S105-112.
[17] Maltais S, Tremblay JP, Perrault LP, et al. The paracrine effect:pivotal mechanism in cell-based cardiac repair[J]. J Cardiovasc Transl Res,2010,3(6):652-662.
[18] Chablais F, Jazwinska A. The regenerative capacity of the zebrafish heart is dependent on TGFbeta signaling[J]. Development,2012,139(11):1921-1930.
[19] Park JS, Chu JS, Tsou AD, et al.The effect of matrix stiffness on the differentiation of mesenchymal stem cells in response to TGF-beta[J]. Biomaterials,2011,32(16):3921-3930.
[20] Rouhi L, Kajbafzadeh AM, Modaresi M, et al.Autologous serum enhances cardiomyocyte differentiation of rat bone marrow mesenchymal stem cells in the presence of transforming growth factor-beta1(TGF-beta1)[J]. In Vitro Cell Dev Biol Anim,2013,49(4):287-294.
[21] Take Y,Morita H.Fragment QRS:what is the meaning?[J].Indian Pacing Electrophysiol J,2012,12(5):213-225.
[22] Dabbagh Kakhki VR, Ayati N, Zakavi SR, et al. Comparison between fragmented QRS and Q waves in myocardial scar detection using myocardial perfusion single photon emission computed tomography[J]. Kardiol Pol,2015, 73(6):437-444.
[23] Cicek Y, Kocaman SA, Durakoglugil ME, et al. Relationship of fragmented QRS with prognostic markers and long-term major adverse cardiac events in patients undergoing coronary artery bypass graft surgery[J]. J Cardiovasc Med(Hagerstown),2015,16(2):112-117.
[24] Wang DD, Tibrewala A, Nguygen P, et al. Fragmented QRS on surface electrocardiogram is not a reliable predictor of myocardial scar, angiographic coronary disease or long term adverse outcomes[J]. Cardiovasc Diagn Ther,2014,4(4):279-286.
[25] Arenal A, Hernandez J, Perez-David E, et al.Do the spatial characteristics of myocardial scar tissue determine the risk of ventricular arrhythmias?[J]. Cardiovasc Res,2012,94(2):324-332.
[26] Demirel F, Adiyaman A, Timmer JR, et al. Myocardial scar characteristics based on cardiac magnetic resonance imaging is associated with ventricular tachyarrhythmia in patients with ischemic cardiomyopathy[J]. Int J Cardiol,2014,177(2):392-399.
[27] Haugaa KH, Smedsrud MK, Steen T, et al.Mechanical dispersion assessed by myocardial strain in patients after myocardial infarction for risk prediction of ventricular arrhythmia[J]. JACC Cardiovasc Imaging,2010,3(3):247-256.
[28] Bernhardt P, Stiller S, Kottmair E, et al. Myocardial scar extent evaluated by cardiac magnetic resonance imaging in ICD patients:relationship to spontaneous VT during long-term follow-up[J].Int J Cardiovasc Imaging,2011,27(6):893-900.
[29] Kwon DH, Hachamovitch R, Adeniyi A, et al. Myocardial scar burden predicts survival benefit with implantable cardioverter defibrillator implantation in patients with severe ischaemic cardiomyopathy: influence of gender[J]. Heart,2014,100(3):206-213.
[30] Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy:the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology(ESC).Developed in collaboration with the European Heart Rhythm Association(EHRA)[J]. Europace,2013,15(8):1070-1118.
[31] Sade LE, Saba S, Marek JJ, et al. The association of left ventricular lead position related to regional scar by speckle-tracking echocardiography with clinical outcomes in patients receiving cardiac resynchronization therapy[J]. J Am Soc Echocardiogr,2014,27(6):648-656.
[32] Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2011,13:29.
[33] Wong JA, Yee R, Stirrat J, et al. Influence of pacing site characteristics on response to cardiac resynchronization therapy[J]. Circ Cardiovasc Imaging,2013,6(4):542-550.

备注/Memo

备注/Memo:
作者简介:蒋娅(1990—),在读硕士,主要从事无创心功能和心电生理的临床应用。Email:654725316@qq.com
通信作者:李波(1966—),主任医师,硕士,主要从事无创心功能和心电生理的临床应用。Email:xgnLiBo1995@sina.com
更新日期/Last Update: 2016-02-20